Exelixis stock price.

Under this program, Exelixis repurchased $127.0 million of the company’s common stock at an average price of $19.22 per share as of Jun 30. Exelixis, Inc. Price, Consensus and EPS Surprise.

Exelixis stock price. Things To Know About Exelixis stock price.

Nov 27, 2023 · NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. Get Exelixis Inc (EXEL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsExelixis Stock Earnings. The value each EXEL share was expected to gain vs. the value that each EXEL share actually gained. Exelixis ( EXEL) reported Q3 2023 earnings per share (EPS) of $0.00, — estimates of $0.10 by 96.63%. In the same quarter last year, Exelixis 's earnings per share (EPS) was $0.23. Exelixis is expected to release next ...ALAMEDA, Calif., January 08, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance ...Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...

Jul 27, 2023 · Current Price. $81.28. Price as of November 30, 2023, 4:00 p.m. ET ... Sarepta Therapeutics (SRPT 1.09%) and Exelixis ... leading to consistently solid financial results and stock market ... The Company’s share price has increased over 300% since 2016 when CABOMETYX® received its first U.S ... who have a deep understanding of the biopharmaceutical industry. At the Annual Meeting, two of Exelixis’ long-tenured directors will not stand for re-election and the Board is recommending the election of Tomas Heyman and Bob ...Web

Last update 09 Jul 2023. XB-002. Last update 09 Jul 2023Web

1 Reason to Buy Exelixis Stock, and 1 Reason to Sell. By Prosper Junior Bakiny – Jul 22, 2022 at 10:15AM Key Points. ... Price as of November 24, 2023, 1:00 p.m. ET.AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON OCTOBER 11, 2000. REGISTRATION NO. 333Exelixis Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EXEL updated stock price target summary.The stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company announced a ... Mar 18, 2023 · And analysts agree: The lowest price target for the stock this year is $20, and the consensus price target is $26, implying an upside of more than 50% from where Exelixis trades today.

Historical daily share price chart and data for Exelixis since 2000 adjusted for splits and dividends. The latest closing stock price for Exelixis as of November 24, 2023 is 21.68. The all-time high Exelixis stock closing price was 49.25 on July 26, 2000. The Exelixis 52-week high stock price is 22.80, which is 5.2% above the current share price.

Exelixis (NASDAQ: EXEL) is making waves in the healthcare sector as a promising stock option. It focuses on developing innovative therapies for various types of cancer, which has recently led to ...Web

The Exelixis stock prediction for 2025 is currently $ 41.74, assuming that Exelixis shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a increase in the EXEL stock price. In 2030, the Exelixis stock will reach $ 216.41 if it maintains its current 10-year average growth rate.Exelixis Today's Change (1.79%) $0.38 Current Price $21.30 Key Data Points Market Cap $7B Day's Range $20.79 - $21.45 52wk Range $15.32 - $22.80 Volume 763,990 Avg Vol 2,321,428 Gross Margin...Overview Stock Screener Earnings Calendar Sectors Nasdaq | EXEL U.S.: Nasdaq Exelixis Inc. Watch list Set a price target alert After Hours Last Updated: Nov 10, 2023 5:06 p.m. EST Delayed...Prices may change from date of publication. With the start of the new school year, things can get hectic. ... Exelixis stock price raised to $29 vs. $25 at OppenheimerJames Rogers is a Financial Columnist for MarketWatch.WebNov 24, 2023 · Complete Exelixis Inc. stock information by Barron's. View real-time EXEL stock price and news, along with industry-best analysis. The stock price of Exelixis (NASDAQ: EXEL), a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company ...ALAMEDA, Calif., January 08, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance ...

Dec 1, 2023 · A high-level overview of Exelixis, Inc. (EXEL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest information on Exelixis Inc (EXEL), a biopharmaceutical firm that discovers and develops treatments for cancer. See its stock price, news, analysis, …The Price and 12 Month EPS chart displays the company's stock price along with the trailing twelve month (TTM) EPS. A company's earnings per share, or EPS, is a key financial metric on its income ...Exelixis, Inc. (EXEL Quick Quote EXEL - Free Report) continues to be one of the outperformers in the choppy biotech industry in 2023. Shares of the company have …Feb 7, 2023 · Exelixis Inc. published this content on 07 February 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 07 February 2023 22:03:02 UTC .

The company has an average price target of $26.67 with a high of $32.00 and a low of $18.00. Below is a summary of how these 9 analysts rated Exelixis over the past 3 months.On June 28, shareholders in the cancer therapeutics company Exelixis ( EXEL -0.29%) got a nasty shock: Its stock price plunged by more than 23% after it delivered worse-than-expected data from a ...

Exelixis : Exelixis ... with no more than 8% in any one stock. ... For investors, Merck also sports a price-to-earnings multiple under 14 and offers a dividend yield of over 3%.WebOn December 4, 2023, Exelixis Inc. (EXEL) showcased strong performance in the stock market, trading near the top of its 52-week range and above its 200-day simple moving average. The price of EXEL shares increased by $0.08 since the market last closed, representing a rise of 0.36%.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Dec 1, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exelixis stock is Moderate Buy based on the current 5 hold ratings and 11 buy ratings for EXEL. The average twelve-month price prediction for Exelixis is $25.44 with a high price target of $32.00 and a low price target of $18.00. The Exelixis stock price has experienced headwinds due to ongoing abbreviated new drug application (ANDA) legal proceedings. We believe that the ANDA trial in Delaware Federal Court in October 2023 will illuminate key facts and related arguments, which should cause those headwinds to dissipate. In these proceedings, we continue to protect the …Dec 1, 2023 · Exelixis Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 21.45. Negative dynamics for Exelixis shares will prevail with possible volatility of 2.353%. Pessimistic target level: 21.18. Optimistic target level: 21.69. Exelixis Trading Up 0.6 %. Shares of NASDAQ:EXEL opened at $21.94 on Monday. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of 78.36, a P/E/G ratio of 1.24 and a beta of 0.57.Implied volatility is determined mathematically by using current option prices in a formula that also includes Standard Volatility (which is based on historical ...

38.88. -1.13. -2.82%. Get Exelixis Inc (EXEL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

NEW: Experience our best charts yet. Discover historical prices for EXEL stock on Yahoo Finance. View daily, weekly or monthly format back to when Exelixis, Inc. …

Its revenue was up 14.6% on a year-over-year basis. Exelixis has generated $0.28 earnings per share over the last year ($0.28 diluted earnings per share) and currently has a price-to-earnings ratio of 80.1. Earnings for Exelixis are expected to grow by 73.33% in the coming year, from $0.60 to $1.04 per share.According to the current price, Exelixis is 143.21% away from the 52-week low. What was the 52-week high for Exelixis stock? The high in the last 52 weeks of Exelixis stock was 22.80. And analysts agree: The lowest price target for the stock this year is $20, and the consensus price target is $26, implying an upside of more than 50% from where Exelixis trades today.The Exelixis stock price gained 1.05% on the last trading day (Wednesday, 29th Nov 2023), rising from $21.05 to $21.27. During the last trading day the stock fluctuated 2.72% from a day low at $20.96 to a day high of $21.53. The price has been going up and down for this period, and there has been a -0.47% loss for the last 2 weeks.The biotech company reported 0% EPS growth last quarter, while sales growth came in at -6%. Exelixis stock earns the No. 48 rank among its peers in the Medical-Biomed/Biotech industry group.Exelixis Stock Price Chart Technical Analysis: The current trend is moderately bearish and EXEL is experiencing selling pressure, which indicates risk of future bearish movement.WebExelixis' US$19.35 share price signals that it might be 49% undervalued. ... the company appears quite good value at a 49% discount to where the stock price trades currently. Valuations are ...View Exelixis, Inc EXEL investment & stock information. Get the latest Exelixis, Inc EXEL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Nov 13, 2023 · Analyst Silvan Tuerkcan from JMP Securities remains neutral on the stock and has a $27.00 price target. Silvan Tuerkcan’s Buy rating for Exelixis’s stock is based on a variety of factors ... The Exelixis stock price has experienced headwinds due to ongoing abbreviated new drug application (ANDA) legal proceedings. We believe that the ANDA trial in Delaware Federal Court in October 2023 will illuminate key facts and related arguments, which should cause those headwinds to dissipate. In these proceedings, we continue to protect the …Complete Exelixis Inc. stock information by Barron's. View real-time EXEL stock price and news, along with industry-best analysis.Analyst Sentiment Leaderboard. DIVIDENDS Dividend Calendar Dividends - WorldInstagram:https://instagram. tax free closed end fundsstock schwcrypto penny6 month bonds During the 2022 bear market, the innovation-fueled Nasdaq shed up to 38% of its value and ended the year lower by 33%. Through the first eight months and change of 2023, the Nasdaq Composite is higher by nearly 32%. Find the latest Exelixis, Inc. (EXEL) stock quote, history, news and other vital information to help you with your stock trading ... nvidia ipo priceyaskawa electric corporation Dec 1, 2023 · According to 14 stock analysts, the average 12-month stock price forecast for Exelixis stock is $26.43, which predicts an increase of 20.46%. The lowest target is $18 and the highest is $32. On average, analysts rate Exelixis stock as a buy. 1964 jefferson nickel Exelixis, Inc.'s (NASDAQ:EXEL) market cap decline of US$208m may not have as much of an impact on institutional owners after a year of 4.0% returns. (Simply Wall St.) 09:00AM. The Smartest Stocks to Buy With $20 Right Now and Hold Forever. (Motley Fool) May-24-23 09:53AM.Complete Exelixis Inc. stock information by Barron's. View real-time EXEL stock price and news, along with industry-best analysis.Key Insights. Given the large stake in the stock by institutions, Exelixis' stock price might be vulnerable to their trading decisions. The top 12 shareholders own 50% of the company